drugset / Trial / NCT01046825
Mature B-Cell Lymphoma And Leukemia Study III
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase III clinical trial using risk-adapted therapy. Treatment outcomes for children with B-cell NHL are excellent. Further improvements in outcome will likely be achieved through more focused study of the biology of the tumors and prospective studies of the late effects of treatment. Toward this end, this study features a spectrum of prospective biologic and late effect studies performed in patients treated with a modified regimen derived from the very successful LMB-96 regimen.
Timeline
- Start
- 2010-09-09
- Primary completion
- 2023-08-31
- Completion
- 2027-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | Cytarabine | Small molecule | — | — |
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Etoposide | Small molecule | — | — |
| Subject | Methotrexate | Small molecule | — | — |
| Subject | Prednisolone | Other / unclassified | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |
| Subject | Vincristine | Small molecule | — | — |
| Background | Leucovorin | Small molecule | — | — |
| Background | Pegfilgrastim | Protein / enzyme biologic | — | — |
| Background | Rasburicase | Protein / enzyme biologic | — | — |
| Background | filgrastim | Protein / enzyme biologic | — | — |